Curaleaf Holdings has asked Aurora Cannabis shareholders to support its takeover proposal that values Aurora at $4.00 per share based on an August 10 reference date. The offer consists of 0.3463 Curaleaf shares plus $0.75 in cash for each Aurora share, equivalent to $75 in cash and roughly 35 Curaleaf shares for every 100 Aurora shares held.
The deal represents a 45% premium to Aurora’s 30‑day volume‑weighted average price of $2.76 as of August 10, 2026. Curaleaf announced the offer on August 18, 2026, and set a tender deadline of December 1, 2026. A webcast hosted by Curaleaf Chairman and CEO Boris Jordan is scheduled for Thursday at 10:30 a.m. ET to discuss the terms with Aurora investors.
If completed, the combined company would operate in 17 countries, generate about $1.5 billion in revenue and nearly $350 million in adjusted EBITDA for the twelve months ended June 30, 2026. Curaleaf projects at least $40 million in annual cost synergies.
Curaleaf’s own shares have risen roughly 50% in the first half of 2026, while Aurora’s stock has fallen about 34% over the same period. Aurora’s net revenue and adjusted EBITDA have declined 14% and 78%, respectively, across the four quarters ended June 30, 2026.
Curaleaf filed a Registration Statement on Form F‑80 with the SEC and a Tender Offer Statement on Schedule 14D‑1F as part of the transaction process. Carson Proxy Advisors is assisting Aurora shareholders with the tender.
